Newborn Pulse Oximetry Screening for Congenital Heart Disease / Монголын Анагаах Ухаан

ABSTRACT

@#Congenital heart disease (CHD) is one of the most common birth defects, with an incidence of nine out of every 1,000 live births. Critical CHD (CCHD) is defined as cardiac lesions that require surgery or cardiac catheterization within the first month (or within the first year by different definitions) of life to prevent death or severe end-organ damage. An early diagnosis and timely intervention can significantly reduce the likelihood of an adverse outcome. However, studies from the United States and other developed countries have shown that as many as 30%–50% of infants with CCHD are discharged after birth without being identified. Pulse oximetry is a tool to measure oxygen saturation, and based on the presence of hypoxemia, many cardiac lesions are detected. Due to its ease of application to the patient, providing results in a timely manner and without the need for calibrating the sensor probe, pulse oximetry offers many advantages as a screening tool. Pulse oximetry was recommended as a screening tool to detect critical CHD in 2011 by the American Academy of Pediatrics and the American Heart Association. Pulse oxymetry screening (POS) for early detection of CCHD is a simple, noninvasive, and inexpensive test, which meets the necessary criteria for inclusion to universal newborn screening panel. Wider acceptance and adoption can significantly decrease morbidity and mortality in infants with CCHD.